Kerry B. (Hrsg.) Barker

Biosimilar Clinical Development: Scientific Considerations and New Methodologies

Ebook (PDF Format)

Biosimilars have the potential to change the way we think about, identify, and manage health problems. They are already impacting both clinical research and patient care, and this impact will only grow as our understanding and technologies improve. Written by a team of experienced specialists in clinical development, this book discusses various potential drug development strategies, the design and analysis of pharmacokinetics (PK) studies, and the design and analysis of efficacy studies.

CHF 56.75

Preise inkl. MwSt. und Versandkosten (Portofrei ab CHF 40.00)

Versandfertig innerhalb 1-3 Werktagen
Versandkostenfrei

Produktdetails

Weitere Autoren: Menon, Sandeep M. (Hrsg.) / D'Agostino, Sr. (Hrsg.) / Xu, Siyan (Hrsg.) / Jin (Hrsg.)

ISBN: 978-1-4822-3170-0
EAN: 9781482231700
Produktnummer: 21955660
Verlag: Taylor & Francis Ltd.
Sprache: Englisch
Erscheinungsjahr: 2016
Seitenangabe: 268 S.
Plattform: PDF
Masse: 3'971 KB
Abbildungen: 31 farbige Abbildungen

Über den Autor

Dr. Kerry B. Barker is the Vice-President and Head of Early Oncology Research Statistics at Pfizer, Dr. Sandeep Menon is the Vice-President and Head of Biostatistics Research and Consulting Center at Pfizer , Dr. Ralph D'Agostino is a professor of Mathematics and Statistics at Boston University, Dr. Siyan Xu is a senior principal biostatistician at Novartis and Dr.Bo Jin is the Director of Biostatistics in Early Oncology Research at Pfizer. All have been involved with biosimilars clinical development across all regions of the world.